South San Francisco Newswire

Comprehensive Real-Time News Feed for South San Francisco, CA.

Results 1 - 20 of 45 for "u:pr-inside.com" in South San Francisco, CA

  1. Cytokinetics to Hold Annual Meeting of StockholdersRead the original story

    Wednesday May 13 | PR-inside.com

    SOUTH SAN FRANCISCO, Calif., May 13, 2015 -- Cytokinetics, Incorporated announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 20, 2015 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics' performance.

    Comment?

  2. Solazyme, Inc. (SZYM) - Alternative Energy - Deals and Alliances Profile - New Market Research ReportRead the original story

    Friday May 8 | PR-inside.com

    It develops wide range renewable oils, and powerhouse ingredients that find applications in nutrition, skin and personal care, sustainable fuels, and other industrial markets. Its proprietary technology transforms a range of plant-based sugars into high-value triglyceride oils, and other bi-products.

    Comment?

  3. New Report Available: Amgen Inc. (AMGN) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Tuesday May 5 | PR-inside.com

    Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats.

    Comment?

  4. Cytokinetics to Announce First Quarter Results on April 30, 2015Read the original story

    Apr 16, 2015 | PR-inside.com

    South San Francisco, CA., April 16, 2015, - Cytokinetics, Incorporated announced today that it is scheduled to report first quarter results on Thursday, April 30, 2015 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

    Comment?

  5. New market study, "Nodality, Inc. - Medical Equipment - Deals and...Read the original story

    Apr 16, 2015 | PR-inside.com

    The company discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients. It develops molecular diagnostics to improve clinical decision-making in cancer and autoimmune diseases, with the products targeting treatment management in hematological malignancies.

    Comment?

  6. Cytokinetics to Present at the 14th Annual Needham Healthcare ConferenceRead the original story

    Apr 8, 2015 | PR-inside.com

    South San Francisco, CA, April 8, 2015 - Cytokinetics, Incorporated announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 11:20 AM at the Westin New York Grand Central in New York, NY. Interested parties may access the live audio of this presentation by visiting the Investor Relations section of the Cytokinetics website at www.cytokinetics.com.

    Comment?

  7. Cytokinetics Announces Publication of Results from Phase II Trial of...Read the original story

    Mar 25, 2015 | PR-inside.com

    Data from Evidence of Effect Trial Provide Support for Novel Mechanism of Action in Neuromuscular Diseases South San Francisco, CA, March 25, 2015 - Cytokinetics, Incorporated announced the publication of a manuscript relating to its fast skeletal muscle troponin activator tirasemtiv in the journal Neurotherapeutics. This publication summarizes results from a Phase IIa "Evidence of Effect" or hypothesis-generating clinical trial which evaluated tirasemtiv in patients with generalized myasthenia gravis .

    Comment?

  8. New Report Available: MPM Capital, L.P. - Medical Equipment - Investment ProfileRead the original story

    Mar 17, 2015 | PR-inside.com

    It focuses investments into biotechnology, medical technology, specialty pharma and related companies that provide medical products and services to the healthcare industry. The firm is structured to invest in healthcare innovation globally, irrespective of geography, stage of development and therapeutic area.

    Comment?

  9. Report Published: "diaDexus, Inc. (DDXS) - Financial and Strategic SWOT Analysis Review"Read the original story

    Mar 15, 2015 | PR-inside.com

    The company develops and commercializes in-vitro diagnostic products for the treatment of cardiovascular disease. Its product includes The PLAC Test.

    Comment?

  10. Cytokinetics Announces Completion of Enrollment in COSMIC-HFRead the original story

    Mar 13, 2015 | PR-inside.com

    Results Expected Later This Year to Inform Potential Progression of Omecamtiv Mecarbil to Phase III SOUTH SAN FRANCISCO, CA, March 13, 2015 - Cytokinetics, Incorporated announced today that COSMIC-HF has completed enrollment of the approximately 450 patients planned in the expansion phase of the clinical trial. In addition, the company announced that over 200 patients have completed the protocol-specified 20-week duration of dosing in this phase of the trial and reaffirmed that results from COSMIC-HF are expected to be available in the second half of 2015.

    Comment?

  11. Fluidigm Corporation (FLDM) - Medical Equipment - Deals and Alliances Profile - New Study ReleasedRead the original story

    Mar 7, 2015 | PR-inside.com

    The company manufactures and markets microfluidic-based chips and instrumentation for biological research. Its products and systems include biomark HD system, C1 system, EP1 system, access array system, chips and kits, DELTagene assays, SNPtype assays, target-specific primers and software.

    Comment?

  12. Cytokinetics Joins Global Movement to Raise Awareness for Rare DiseasesRead the original story

    Feb 27, 2015 | PR-inside.com

    SOUTH SAN FRANCISCO, CA, February 27, 2015 - Cytokinetics, Incorporated announced today that it is joining forces on February 28 with patients and health care advocates in the United States and globally to raise awareness for Rare Disease Day . Rare Disease Day is dedicated to elevating public understanding of rare diseases and calling attention to the special challenges faced by patients with rare diseases and the support community around them.

    Comment?

  13. Cytokinetics Announces Publication of Preclinical Data Relating to...Read the original story

    Feb 26, 2015 | PR-inside.com

    Manuscript Supports Rationale for Development of CK-2127107 in Diseases Associated with Muscle Weakness and Fatigue South San Francisco, CA, February 26, 2015 - Cytokinetics, Incorporated announced the publication of a manuscript relating to its fast skeletal muscle troponin activator CK-2127107 in The Journal of Pharmacology and Experimental Therapeutics. This publication relates to a preclinical evaluation of CK-2127107 in a rat model of heart failure that demonstrated CK-2127107 was associated with increased exercise performance in this model.

    Comment?

  14. Cytokinetics to Present at Healthcare Conferences in MarchRead the original story

    Feb 24, 2015 | PR-inside.com

    South San Francisco, CA, February 24, 2015 - Cytokinetics, Incorporated announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following healthcare conferences: Cowen and Company 35 Annual Health Care Conference Date: Tuesday, March 3, 2015 Time: 11:20 AM Eastern Time Location: Boston Marriott Copley Place Hotel, Boston, MA 27 Annual ROTH Conference Date: Monday, March 9, 2015 Time: 8:30 AM Pacific Time Location: Ritz-Carlton, Laguna Nigel, Dana Point, CA Interested parties may access the live audio of this presentation by visiting the Investor Relations section of the Cytokinetics website at www.cytokinetics.com.

    Comment?

  15. Portola Pharmaceuticals, Inc. (PTLA) - Pharmaceuticals & Healthcare - ...Read the original story

    Feb 20, 2015 | PR-inside.com

    It undertakes the discovery and development of innovative therapeutics for the treatment of cardiovascular, inflammation, and oncology indications. The company's product portfolio includes Betrixaban, Andexanet Alfa , PRT2607, and PRT2070.

    Comment?

  16. Market Report, "Nodality, Inc. - Pharmaceuticals & Healthcare - Deals ...Read the original story

    Feb 19, 2015 | PR-inside.com

    Nodality, Inc. is a biotechnology company. The company discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients.

    Comment?

  17. Cytokinetics, Incorporated Reports Fourth Quarter 2014 Financial ResultsRead the original story

    Feb 12, 2015 | PR-inside.com

    Ongoing Regulatory Interactions in US and Europe Inform Progression of Tirasemtiv to Phase III COSMIC-HF Nears Completion of Enrollment with Results Expected Later This Year Company Exceeded Financial Guidance in 2014 and Provides Milestones and Financial Guidance for 2015 SOUTH SAN FRANCISCO, CA, February 12, 2015 - Cytokinetics, Incorporated reported total research and development revenues for the fourth quarter of 2014 were $21.8 million, compared to $24.3 million during the same period in 2013. The net income for the fourth quarter was $8.4 million, or $0.23 per basic and diluted share.

    Comment?

  18. Recent Study: Poniard Pharmaceuticals, Inc. (PARD) - Pharmaceuticals...Read the original story

    Feb 12, 2015 | PR-inside.com

    The company focused on developing picoplatin product, which is a new generation platinum based cancer therapy. Picoplatin is designed to overcome platinum resistance in the treatment of solid tumors.

    Comment?

  19. Now Available: Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Feb 11, 2015 | PR-inside.com

    The company develops therapeutics for the treatment of central nervous system disorders. Its products include probuphine used for the treatment of opioid addiction, iloperidone used for the treatment of schizophrenia and related psychotic disorders.

    Comment?

  20. New Market Report: Talon Therapeutics, Inc. (TLON) - Pharmaceuticals...Read the original story

    Feb 11, 2015 | PR-inside.com

    Talon Therapeutics, Inc. is a biopharmaceutical company. It researches, develops and commercializes products for cancer.

    Comment?

South San Francisco Job Listings
View or post South San Francisco job listings on Topix.
South San Francisco Real Estate
News, listings, and foreclosures in South San Francisco from Topix.
South San Francisco Mortgages
Find mortgage rates in South San Francisco on Topix.